2025년 08월 22일 금요일
 
 
  현재위치 > 뉴스지닷컴 > Business

랜섬웨어부터 돼지도살까지... 노련해진 사기행각

 

정치

 

경제

 

사회

 

생활

 

문화

 

국제

 

과학기술

 

연예

 

스포츠

 

자동차

 

부동산

 

경영

 

영업

 

미디어

 

신상품

 

교육

 

학회

 

신간

 

공지사항

 

칼럼

 

캠페인
한살림 ‘우리는 한쌀림’ 쌀 소비 캠페인 시...
1000만원짜리 인공와우, 건강보험 지원 ‘평...
- - - - - - -
 

RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.

뉴스일자: 2021-08-27

SAN CARLOS, CALIF.-- August 26, 2021 -- RubrYc Therapeutics, Inc. (“RubrYc”) and iBio, Inc. (“iBio”, NYSEA: IBIO) announced today the closing of RubrYc’s Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research, development, and commercialization of epitope-targeted antibody therapeutics. With this transaction, iBio becomes an important strategic investor with its $7.5M investment in the RubrYc’s Series A2 Preferred equity, joining Third Point Ventures, Paladin Capital Group, Vital Venture Capital, and Hayan Health Networks in the Company’s investor syndicate. Additionally, iBio secures exclusive worldwide rights to advance RubrYc’s lead program, RTX-003, a CD25 targeted monoclonal antibody for selective depletion of regulatory T cells in the solid tumor microenvironment.

The collaboration will allow the parties to combine RubrYc’s Discovery Engine and antibody discovery expertise with iBio’s capabilities as a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System® to create novel therapies for patients in need. Under the terms of the agreement RubrYc will be responsible for the discovery of epitope-targeted drug candidates using RubrYc’s proprietary Meso-scale Engineered Molecules to steer antibody discovery campaigns to particular epitopes on mutually agreeable disease targets. iBio will collaborate in discovery campaigns and will be responsible for conducting preclinical, clinical and commercialization activities for the selected drug candidates from the collaboration.

Under the terms of the agreement, if iBio develops and commercializes multiple candidates produced in the collaboration, RubrYc could receive more than $84 million as milestone payments related to discovery and development activities. RubrYc may also receive royalties on worldwide net sales of any commercial products developed through the collaboration.

“We are excited to collaborate with iBio,” stated RubrYc’s Co-Founder and Chief Executive Officer, Isaac Bright, MD, “an ambitious partner whose strategic transformation is aligned with our vision to efficiently discover and develop epitope-targeted therapies that promise to outperform conventionally discovered precedent molecules. iBio is also a fantastic partner to advance our lead campaign, RTX-003, an anti-CD25 monoclonal antibody we’ve discovered that shows tremendous promise as a regulatory T Cell depletor for multiple solid tumor indications.”

“We expect RubrYc’s epitope-targeting antibody discovery technology to drive differentiated campaigns attacking challenging targets, and to efficiently confer multiple opportunities to discover and advance epitope-advantaged antibodies against well-characterized oncology targets,” said iBio’s Chief Executive Officer, Tom Issett who will join RubrYc’s Board of Directors. “RTX-003 is a remarkable asset to add to our therapeutic pipeline, and we look forward to completing IND-enabling activities as we continue to expand our discovery and development capabilities.”



 전체뉴스목록으로

Correcting And Replacing: Japan's No. 1 Brand KATE Unveils Strategic Moves To Expand Business And Boost Recognition In Asia
Andersen Consulting Announces Collaboration Agreement with Virtual, Inc.
Philippine Government and Sutherland Launch AI Academy to Equip Filipinos with Future-Ready Skills
Omdia Strengthens APAC Leadership with Addition of Tech Research Asia Team
Kinly Merges with Yorktel to Accelerate Global Growth and Expand Managed Services and Systems Integration Portfolios
IFF Expands Innovation Center in Singapore with New Immersive Experience Hub
[Executive Corner] webOS: Powering Our Next Growth Chapter

 

DEWA Reports Record H1 Revenue of AED 14.6 Billion and Approves AED 3....
Connecting the Disconnected: How Film Director Fred Scott Brought LG’...
Andersen Consulting Adds Collaborating Firm 460degrees
Megaport Surpasses 1,000 Enabled Locations Worldwide
ALT5 Sigma Launches $1.5B Direct Offering And Private Placement To Beg...
LG xboom by will.i.am: Sound and Style Designed for Life’s Genuine Mo...
Energy Vault Secures Final FIRB Approval and Completes Acquisition of ...

 


공지사항
뉴스지 한자 표기에 대만식 음차 표기 '纽斯集 니우시지' 병기
베네프롬 베네인투 중문 표기 宝乃福牧 宝乃因托(寶乃福牧 寶...
미디어아우어 Mediaour 媒体我们 媒體我們 MO 엠오 媒我 媒我
알리우브 Alliuv 阿备: 阿联有备, 알뜰 Althle 阿特益
알리알 Allial 중문 표기 阿利尔 阿利爾
뉴퍼스트 New1st 중문 표기 纽壹新(번체 紐壹新), N1 纽1
엔코스모스 : 이씨 'EnCosmos : EC' 중문 표기 以宙
아이디어론 Idearon 중문 표기 以迪论 以迪論
바이오이니 Bioini 중문 표기 必药研 必藥硏
오스프롬 Ausfrom 奥斯福牧, 웰프롬 Welfrom 卫福牧
에너프롬 Enerfrom 额能福牧 에너유비 Eneruv 额能有备
알프롬 Alfrom 중문 표기 阿尔福牧 阿爾福牧

 

회사소개 | 인재채용 | 이용약관 | 개인정보취급방침 | 청소년보호정책 | 책임한계와 법적고지 | 이메일주소무단수집거부 | 고객센터

기사제보 이메일 news@newsji.com, 전화 050 2222 0002, 팩스 050 2222 0111, 주소 : 서울 구로구 가마산로 27길 60 1-37호

인터넷뉴스서비스사업등록 : 서울 자00447, 등록일자 : 2013.12.23., 뉴스배열 및 청소년보호의 책임 : 대표 CEO

Copyright ⓒ All rights reserved..